Introduction {#Sec1}
============

The last consensus on diagnostic criteria for dementia with Lewy Bodies (DLB), states that "tremor is less frequent than in Parkinson's disease (PD)" \[[@CR1]\] but does not detail the types and relative prevalence of tremor, despite earlier studies reporting a prevalence of 40 % for rest and 30 % for action (kinetic-postural) tremor \[[@CR2], [@CR3]\].

Generally rest tremor is considered specific for PD, while postural and action (or intentional) tremor are attributed to essential tremor (ET), although exceptions to this rule are clearly reported \[[@CR4]--[@CR6]\]. The prevalence of these tremors have not been investigated in DLB after the early reports, nor was described the prevalence of other types of tremor which are considered infrequent but specific to PD, as head and face tremors \[[@CR7], [@CR8]\], re--emergent \[[@CR6], [@CR9]\], pseudo-orthostatic or standing tremor \[[@CR5], [@CR10]--[@CR13]\]. In addition, while there are some small studies reporting an improvement of general motor features in DLB with acute [l]{.smallcaps}-Dopa challenge \[[@CR14]\], the specific response of tremors to treatments has been investigated in only one early study \[[@CR15]\].

The clarification of the different tremor types and response to treatment in DLB could improve clinical recognition of DLB, but mostly, understanding tremor in DLB, would provide clarity to recent controversial debates \[[@CR16]--[@CR24]\] on the long term outcome of patients putatively affected by ET. Several reports showed that some ET patients, during follow-up may present with additional PD features, dopamine transporter capitation abnormalities, or cognitive abnormalities, and may present with Lewy bodies at the autopsy \[[@CR16]--[@CR21]\]. These observations were, more or less dismissively, challenged in three different editorials \[[@CR22]--[@CR24]\]. Yet, these discussions did not consider at all that the action (kinetic, postural) tremors, of DLB may be erroneously attributed to ET.

Therefore, our study aims to show characteristics and treatment sensitivity of tremor in DLB in comparison with tremor in PD and ET, in order to be of help to neurologists attempting categorization of patients.

An incident cohort of DLB patients was evaluated and followed for two years and compared with two cohorts of incident PD and ET patients. Detailed and extensive evaluation of any tremors present was carried out and response to acute and chronic treatments was also investigated.

Methods {#Sec2}
=======

All new referrals to our movement disorders and memory clinics in the years 2005--2009, (202 patients) diagnosed with DLB, PD, or ET, according to the accepted clinical criteria \[[@CR1], [@CR4], [@CR25]\] were enrolled in the study. Exclusion criteria were any prior exposure to neuroleptic drugs, the presence of dystonia and the presence of classic orthostatic tremor. The PD patients with dementia (PDD) were excluded because of the confounding effects of treatments.

All patients tested negative for the G20195 mutations in the LRRK2 gene \[[@CR26]\] as a high prevalence of mixed tremor has been described in this condition \[[@CR27]\]. All patients were followed for a minimum of two years to confirm/challenge diagnosis.

The study was approved by our local ethical committee and was carried out according to the declaration of Helsinki and subsequent revisions \[[@CR28]\]. Patients (or caregivers) signed a written informed consent and authorization was obtained for disclosure (consent-to-disclose) of any recognizable persons in videos. All patients received a full neurological, neuropsychological, neuroimaging and neuropsychiatric evaluation, as reported in Online Resource 1, and as described in previous studies on the same cohort \[[@CR29]--[@CR32]\]. Observation and recording of tremors were performed only in dopaminergic drugs naive patients (all DLB and 52 PD patients) or after withdrawal of [l]{.smallcaps}-Dopa (48 h) or dopamine agonist (72 h) treatments (13 PD patients).

Tremor was rated using the Tremor Research Group Rating Scale (TRGRS) \[[@CR6]\] quantified clinically according to the TRGRS items. Face and jaw tremor were clustered in a single item, tongue tremor was omitted as this was not observed, and items 10 and 11 (hand writing and holding pencil) were omitted as these items were not collected in all patients. Two supplementary categories, absent in the TRGRS rating scale were also applied: re-emergent tremor of the arm indicating "delayed re-emergence of rest tremor when the arm was postured" \[[@CR9]\] and standing overflow indicating overflow of rest or postural tremor, when standing, to body districts not primarily affected by the tremor. Standing tremor was defined according to the TRGRS scale, and indicated the pseudo-orthostatic tremor with the low frequency of parkinsonian tremor or ET, described in PD or genetic PD \[[@CR10]--[@CR13]\]. Tremors frequencies and amplitudes were also quantified by Electromyography (EMG) as described in our previous papers \[[@CR11], [@CR12], [@CR33]\] and in Online Resource 1.

Acute drug challenge was performed in 34 ET, 24 DLB and 27 PD patients. Acute treatments were evaluated in the three groups with blinded procedures. Alcohol test and acute [l]{.smallcaps}-Dopa challenges were performed according to the described protocols \[[@CR15], [@CR34]--[@CR36]\]. An alcohol test was performed in all ET, PD and DLB patients with tremor, in blinded protocols. A target of 0.8 ‰ (0.8 g/L) alcohol was reached by administering in 5 min, 8 fluid oz of orange juice with artificial nonalcohol Rum flavour (placebo) or orange juice with 40 % alcohol Rum. The needed amount of alcohol was calculated for each patient according to published body water formulas. The TRGRS rating was performed by examiners unaware of the administered substance 30--45 min after the administration according to published observations on maximal tremor responses to ethanol administration \[[@CR34]\].

Double blind cross-over acute [l]{.smallcaps}-Dopa challenges (single oral adminiostration [l]{.smallcaps}-Dopa/carbidopa 250/25 mg) \[[@CR36]\] were performed in patients never exposed to [l]{.smallcaps}-Dopa with the TRGRS rated by examiners 90--110 min after drug or placebo intake.

Primidone effect (250--500 mg/day) was evaluated in eight DLB patients, who were taking this drug for presumed ET prior to referral to our clinics. In these patients TRGRS ratings and tremor assessments were performed during primidone treatment and two weeks after withdrawal.

During the follow-up period all DLB and PD patients received oral [l]{.smallcaps}-Dopa treatment and other treatments according to their needs. Tremor ratings were repeated every two to four months; the chronic treatment effect evaluation was performed six months after the initial assessment.

Statistics {#Sec3}
----------

Demographic, clinical and neuropsychological/neuropsychiatric differences between groups and time of evaluation were estimated using either analysis of variance for continuous variables (One-way ANOVA; ANOVA for repeated measure) or non-parametric procedures as appropriate (Wilcoxon test). Between-groups differences in the prevalence of the specific types of tremor were investigated using the chi-square test. Stepwise logistic regression and ROC analyses were used to assess the best group predictor among the types of tremor. Post hoc clustering of TRGRS scores was applied to treatment effect evaluations in order to simplify graphic rendering of data.

Correlations between tremor scores and neuropsychological tests were not applied because the range of scores for cognitive variables clustered specifically in the DLB population. All analyses were conducted using statistical package SSPS 16.

Results {#Sec4}
=======

Patients characterization {#Sec5}
-------------------------

Among the 202 new referrals to our movement disorders and memory clinics during the years 2005--2009, 111 were initially diagnosed with PD, 61 with DLB and 40 with ET.

Within two years from the ET diagnosis, six patients were re-classified as DLB due to the appearance of cognitive decline with all core and supportive consensus elements \[[@CR1]\], including REM sleep behaviour disorder (RBD), hallucinations, EEG abnormalities, and cognitive fluctuations. In these patients DLB categorization, instead of PD with Dementia (PDD), was considered acceptable despite the fact that tremor had appeared before or was concomitant with cognitive decline, as the tremor observed at first referral was purely intentional-kinetic and all six had been addressed to referral as ET patients and two of them were temporarily treated with primidone until our re-evaluation. Six more patients were treated with primidone according to putative ET diagnosis, but in these patients the diagnosis of DLB was completed at first referral. Figure [1](#Fig1){ref-type="fig"} shows the study design-flow chart with categorization of patients.Fig. 1Flow chart of the study: referral to clinics, selection of patients according to instrumental evaluation proposed by Consortium Consensus criteria, and drug effect assessments. The comparative analysis was performed only in patients whose diagnosis was not challenged during the follow-up. The *asterisk* indicates that the two patients who developed PDD during follow-up were considered in the 65 patients of the PD group

Thus, a total of 67 patients were ultimately classified as DLB and 34 as ET. Two PD patients, presenting with rest/action and standing tremor, developed cognitive impairment and neuropsychiatric symptoms and were reclassified PDD \[[@CR37]\] .

Demographic and clinical characteristics, with statistical comparisons, of the three groups at baseline and follow up are reported in Table [1](#Tab1){ref-type="table"}. Age, results of cognitive tests and the degree of cognitive decline at follow-up significantly separated DLB patients from PD and ET. Onset of tremor, onset of dementia and other clinical characteristics in the eight patients treated with primidone prior to our re-classification into DLB was not statistically different in comparison to the other 22 tremulous DLB patients.Table 1Demographic and clinical characteristics of groupsDLB (*n* = 67)PD (*n* = 111)ET (*n* = 34)*p* (between)Age72.15 (5.43)66.52 (8.84)67.79 (3.73)\<0.005^a^Gender (F/M)35/3151/6016/18NSDisease duration2.86 (0.95)4.07 (3.1)4.7 (1.91)\<0.001^a^UPDRS III Baseline26.98 (5.14)24.47 (12.4)NA\<0.001^b^ Followup21.61 (5.28)18.01 (11.44)NA *p* (within)\<0.001\<0.001MMSE Baseline18.11 (3.27)28.07 (1.5)28.7 (1.5)\<0.001^a^ Followup12.95 (2.78)26.82 (1.93)27.91 (2.1) *p* (within)\<0.001\<0.001NSDRS2 Baseline84.05 (12.82)136.89 (7.08)136.29 (2.6)\<0.001^a^ Followup61.61 (12.85)132.04 (8.73)135.78 (3.2) *p* (within)\<0.001\<0.001NSFAB Baseline12.41 (1.53)17.09 (1.13)17.54 (0.8)\<0.001^a^ Followup9.67 (1.36)15.48 (1.3)17.46 (1.1) *p* (within)\<0.001\<0.001NSCAF Baseline2.95 (1.4)0.05 (0.42)0\<0.001^a^ Followup5.13 (1.31)0.24 (1.03)0 *p* (within)\<0.001\<0.001NANPI Baseline20.74 (1.6)7.6 (2.84)1.8 (1.7)\<0.001^b,d^ Followup28.74 (1.60)8.61 (4.14)1.9 (1.5) *p* (within)\<0.001\<0.001NSRBD (n/%) Baseline58 (86.6)47 (42.3)0\<0.001^c^ Followup62 (92.5)70 (63.1)0 *p* (within)NS0.033NAVH(*n*/%) Baseline49 (73.1)00NA Followup62 (92.5)31 (27.9)0 *p* (within)NSNANAAll values represent mean (SD, when not otherwise stated). Reported *p* values compare between groups (DLB, PD and ET) and within groups (baseline and follow-up). The*p* values have been calculated using Oneway ANOVA with Bonferroni corrections for parametric variables and *χ*^2^ for categorical variables. Disease duration indicates evidence of cognitive decline in DLB*MMSE* Mini Mental State Examination, *NP* neuropsychiatry inventory, *FAB* frontal assessment battery, *DRS-2* Dementia Rating Scale-2, *CAF* clinician assessment of fluctuation, *UPDRS-III* Unified Parkinson's Disease Rating Scale-subscale III, *H/Y* Hoehn/Yahr staging, *RBD* REM sleep behavior disorders, *VH* visual hallucinations (also including benign VH), *NA* not applicable, *NS* not significant^a^DLB different from PD and ET^b^ET different from PD and DLB^c^DLB different from PD^d^PD different from ET

Prevalence of tremor {#Sec6}
--------------------

Tremor was observed in 30 DLB and 65 PD patients. Overall, patients with tremor represented 44.77 % of the DLB cohort (tDLB) and 58.56 % of the PD cohort (tPD). Their characteristics at baseline and follow up are reported in Table [2](#Tab2){ref-type="table"}; there were minor differences between tDLB and nontremulous DLB (age, disease duration and cognitive function) but no differences between PD subgroups.Table 2Comparison between tremulous and non-tremulous patients within the DLB and PD groupsDLB (*n* = 67)PD (*n* = 111)Tremor (30)Non-tremor (37)*p*Tremor (65)Non-tremor (46)*p*Age73.9 (5.17)70.74 (5.3)0.01764.63 (9.82)69.19 (6.44)0.007Disease duration2.13 (0.86)3.45 (0.5)\<0.0014.3 (3.31)5.23 (2.86)NSUPDRS III25.5 (4.61)28.18 (5.3)0.03223.52 (13.04)25.82 (11.43)NSMMSE19.03 (2.56)17.37 (3.61)0.03928.09 (1.72)28.04 (1.31)NSDRS287.96 (7.69)80.89 (15.19)0.024136.16 (8.25)137.91 (4.9)NSFAB12.36 (1.69)12.45 (1.42)NS17.03 (1.22)17.17 (0.99)NSCAF3.2 (1.34)2.75 (1.44)NS0.09 (0.55)0NSNPI20.7 (1.55)20.78 (1.66)NS7.27 (3.14)8.19 (2.26)NSRBD (*n*)2830NS2918NSVH (*n*)2425NS00NAAll values represent mean (SD). *p* values have been calculated using Oneway ANOVA with Bonferroni corrections for parametric variables and *χ*^2^ for categorical variables*MMSE* Mini Mental State Examination, *NP* neuropsychiatry inventory, *FAB* frontal assessment battery, *DRS-2* Dementia Rating Scale-2, *CAF* clinician assessment of fluctuation, *UPDRS-III* Unified Parkinson's Disease Rating Scale-subscale III, *H/Y* Hoehn/Yahr staging, *RBD* REM sleep behavior disorders, *VH* visual hallucinations (also including benign VH), *NA* not applicable, *NS* not significant

Phenomenology of tremors and relative prevalence {#Sec7}
------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows severity and prevalence of tremor types in the tDLB, tPD and ET groups based on the TRGRS scores. The table shows that the full range of tremors, including head and face tremors, was observed with different severity and prevalence in the three groups of patients. Limb tremor was more frequently bilateral in tDLB as compared to tPD (73.3 % vs. 9.2 %, *χ*^2^ = 40.6; *p* \< 0.001).Table 3Severity of tremor types as per TRGRS scoresTRGRSDLB (*n* *=* 30)tPD (*n* = 65)ET (*n* *=* 34) % (*n*)Mean ± SDFreq-HzSide B % (*n*) % (*n*)Mean ± SDFreq-HzSide B % (*n*) % (*n*)Mean ± SDFreq-HzSide B % (*n*)1. Head27 (8)1.02.5--4.8--3 (2)1.02.4--4.9--29 (10)1.30 ± 0.52.5--5.2--2. Face43 (13)1.31 ± 0.54.1--7.2--25 (16)1.31 ± 0.54.2--6.9----------3. Voice----------------17 (6)1.25 ± 0.5NA--4. a. Rest arm87 (26)1.77 ± 0.64.9--7.257 (16)82 (53)2.08 ± 0.84.9--7.18 (4)9 (3)1.05.2--7.4-- (3) b. Forward arm57 (17)2.24 ± 0.44.3--7.559 (10)46 (30)1.50 ± 0.74.6--7.410 (3)100 (34)1.94 ± 0.75.4--7.4100 (34) c. Lateral arm57 (17)2.00 ± 0.84.8--7.259 (10)15 (10)1.50 ± 0.74.3--7.310 (1)100 (34)2.00 ± 0.85.2--7.3100 (34) b-c\* reemergent57 (17)19 (12) d. Kinetic60 (18)1.89 ± 0.74.9--7.389 (16)15 (10)1.60 ± 0.74.7--7.110 (1)100 (34)1.85 ± 0.65.1--7.1100 (34) e. Walking80 (24)2.25 ± 0.85.1--7.568 (17)72 (47)1.74 ± 0.74.3--7.626 (12)--------5. Trunk27 (8)1.37 ± 0.54.0--7.2--5 (3)1.334.1--7.0--9 (3)1.665.1--7.0--6. Action leg53 (16)1.124.2--6.944 (7)3 (2)1.04.3--7.40 (0)56 (19)1.37 ± 0.55.3--7.3100 (19)7. Rest leg53 (16)1.31 ± 0.54.2--7.075 (12)45 (29)1.31 ± 0.54.1--7.231 (9)3 (1)1.05.2--7.3-- (1)8. Standing53 (16)2.25 ± 0.74.6--7.3--5 (3)2.335.1--7.2--3 (1)1.05.1--7.1-- (1)\*with overflow47 (14)3 (2)9. Spiral drawing50 (15)1.87 ± 0.6NA67 (10)15 (10)1.40 ± 0.5NA20 (2)100 (34)2.18 ± 0.8NA100 (34)10. Water pouring47 (14)1.71 ± 0.7NA71 (10)12 (8)1.25 ± 0.5NA25 (2)100 (34)2.12 ± 0.8NA100 (34)Item of the TRGRS are reported on the left, face tremor in the table is the average for each patient of face and jaw tremor. Tongue tremor was not observed. Items 10 and 11 are omitted as not rated in all patients Percentages represent the prevalence of each item in the group (score \> 1) and are approximated to the following unit if \>0.4The re-emergent item 4 b-c\* indicates forward and lateral arm tremor appearing not earlier than 5 s from acquiring the posture. Standing \*with overflow indicates spreading of tremor from affected arms to other body parts when standing. These supplementary items were not specifically rated as not applicable, but amplitude scores were reported in items 4\* and 8TRGRS scores are reported as mean ± SD (standard deviation). SD scores are not reported if *n* \< 4.  Side is coded as bilateral B versus unilateral predominant (TRGRS score one side being \>50 % of the score of the controlateral side)*NA* not applicable available

The ET tremor was bilateral as a result of selection criteria \[[@CR3],[@CR4]\]. The overlap of tremor types in the same patients is graphically represented in Fig. [2](#Fig2){ref-type="fig"}, and Table [3](#Tab3){ref-type="table"} shows that tDLB was characterized by several tremor types including overlapping mixtures of head and face, rest, postural, action (spiral drawing, pouring water) and walking (re-emergence of rest arm tremor when walking) tremor. Almost all of the tDLB patients (97 %) expressed more than one type of tremor.Fig. 2Graphic representation of prevalence of mixed tremor and overlap of tremors in tDLB, tPD and ET. Notice the complexity of mixed forms of tremor in tDLB as compared to tPD and ET. The *circle* or "*pie*" graph on the *upper* half shows the general categories of mixed (any combination) **a** or isolated forms of tremor, (rest) **b**. The ring or exploded "doughnut" graph below each *pie* represents separate subcategories of tremors in the same populations, as marked by following symbols: *m* mixed, **m1**: sum of action postural rest arm, action leg, + walking tremor; **m2**: rest + action + walking tremor; **m3**: rest + action + postural + walking tremor; **m4**: rest + action + walking + standing tremor; **m5**: rest + action + walking + postural arm + standing tremor; **m6**: rest + walking tremor; **m7**: rest + walking + postural tremor; **m8**: action + postural tremor; **m** **+** **f**: mixed + face tremor; **m** **+** **h**: mixed + head tremor; **m** **+** **h/f**: mixed + head + face tremor; **m** **+** **h/V**: mixed +head + voice

Head and face tremor was more frequent in tDLB compared to tPD (26.7 % vs. 3.1 % for head tremor *χ*^2^ = 12.1 *p* = 0.001; 40.3 % vs. 24.6 % for face tremor; *χ*^2^ = 3.4 *p* = 0.06). Voice tremor (bleating voice) was observed only in 6 ET (17.6 %).

For tDLB, 44.9% presented with a complex pattern of mixed tremor which consisted of rest, postural, and action tremor and these were associated with walking and/or standing tremor.

This mixed tremor appeared as hand pill-rolling tremor at rest and when walking but action tremor was also evident when patients attempted to perform the spiral drawing/pouring water TRGRS tasks or when the patient was asked to write.

Standing posture elicited tremor of lower limbs (standing or pseudo-orthostatic tremor) in 53.3 % of tDLB patients, and 4.6 % of PD patients (*χ*^2^ = 24.4; *p* \< 0.001). Leg tremor disappeared when walking whilst tremor of arms appeared. Only one ET patient showed standing tremor, but no walking tremor. Two PD patients with standing tremor presented during follow-up with features of PDD.

A specific characteristics of the mixed tremor observed in DLB patients was an overflow phenomenon elicited by the standing posture with outstretched arms, characterised by the diffusion of tremor to all the different body parts; this overflow was observed in 46.6 % of DLB patients but only in 3.1 % of PD patients (*χ*^2^ = 27.8; *p* \< 0.001). This overflow tremor appeared as hand pill-rolling tremor at rest and when walking but kinetic tremor was also evident when patients were attempting the spiral drawing/pouring water TRGRS tasks or when the patient was asked to write. When these patients were evaluated in a standing position with outstretched arms, tremor appeared in the hands with a latency of 3--15 s and a progressive overflow to lower limbs was observed in 5--30 s. The latency of rest tremor reappearance when acquiring the outstretched arm position was 10.2 ± 4.63 s which contrasted with the almost immediate occurrence of postural tremor in ET, at 1.68 ± 2.27 s (Wilcoxon tests, *Z* = −2.93, *p* = 0.003).

Figure [3](#Fig3){ref-type="fig"} shows the EMG pattern of progressive overflow. The TRGRS scores or tremor frequencies were not statistically different when rest, postural or action tremors were compared with tremor appearing in standing position (*F* = 0.57; *p* = 0.68 for TRGRS score; *F* = 0.46; *p* = 0.76 for frequencies).Fig. 3Frequency analysis and power spectra of tremor at rest and during standing with wing beating arm posture in a patient affected by DLB. EXTENSOR CARPI ULNARIS = ECU; DELTOID = DEL; VASTUS MEDIALIS = VM; TIBIALIS ANTERIOR = TA Horizontal scales represent frequencies in Hz, (0--16 Hz) amplitude of random noise frequencies are 0.2--0.6 μV^2^. A vertical red line connects 5.6 Hz frequencies, which is the specific tremor frequency in this patient. Horizontal arrows point to minor frequency variations (range 0.5--01 Hz) of the peak amplitude. Notice overflow during standing posture for the same districts involved by the rest tremor to other body districts

Combinations of different types of tremor were observed in 45 PD patients but 29 % of these patients presented simply with a combination of rest and walking tremors. (Fig. [2](#Fig2){ref-type="fig"}).

The classic walking tremor was observed in 80 % of tDLB and 72.3 % of tPD patients but in none of ET patients.

Isolated arm rest tremor was observed in only 3.3 % of DLB patients compared with 30.8 % of PD (*χ*^2^ = 5.6; *p* = 0.02). The tDLB patients did not present with isolated postural or action tremor nor the combination of the two; instead this tremor pattern was observed in 70.6 % of ET patients. Tremor frequencies did not differentiate specific tremor patterns although the head tremor had a significantly lower frequency than rest and postural (Wilcoxon test, Z = −3.6, *Z* = −3.1, respectively; *p* \< 0.001; Table [3](#Tab3){ref-type="table"}). Additional information is detailed in Online resource 2.

Regression analysis {#Sec8}
-------------------

In a stepwise regression analysis of the types of tremor observed, the standing tremor proved to be the best predictor of membership in a disease group (*B* = −1.80; Wald = 17.88; *p* \< 0.001; 95 % CI: 0.071, 0.38). Specifically, the presence of standing tremor correctly predicted 46.7 % of tDLB patients, and this percentage increased to 53.5 % when standing and rest tremors entered together in the model (for rest tremor, *B* = −0.47; Wald = 4.74; *p* = 0.03; 95 % CI: 1.05, 2.47). Conversely, the absence of standing tremor itself correctly predicted 96.9 % of tPD suggesting that standing tremor is rare in PD. Roc analysis is reported in Online resource 3.

Effect of treatments {#Sec9}
--------------------

### Acute treatments {#Sec10}

[l]{.smallcaps}-Dopa significantly reduced tremor only in the tDLB group (effect of drug, *F* = 8.56, *p* = 0.001; mean difference on TRGRS total score = 2.05, SE = 0.41, 95 % CI 0.84--3.24, *p* \< 0.001 Bonferroni corrected) while it was ineffective in ET patients. It did improve tremor in a proportion of tPD patients but this improvement was not significant. An acute alcohol test significantly reduced tremor in ET (effect of drug, *F* = 104.7, *p* \< 0.001; mean difference on TRGRS total score = 6.88, SE = 0.37, 95 % CI 5.82--7.94, *p* \< 0.001 Bonferroni corrected) but was ineffective in tDLB and tPD patients. Acute drug response is depicted in Fig. [4](#Fig4){ref-type="fig"}a as a change in total TRGRS score, as no differences in body distribution or the type of tremors were noted following drug administrations.Fig. 4Response to acute drug challenge and chronic treatment. The scores are expressed as mean TRGRS scores. *Bars* represent the SE. \* *p* \< 0.01 **a**: acute treatment. Total TRGRS scores. Improvement after [l]{.smallcaps}-Dopa administration was significant only in tDLB group (*p* \< 0.001). Acute alcohol test improved tremor only in ET (*p* \< 0.001). **b** Tremor in chronically treated patients clustered scores. Rest tremor is the sum of head, face, rest arms and rest leg items; postural tremor is the sum of forward arm and lateral arm items; action is the sum of kinetic, action leg, spiral and water items, mixed tremor defines any combination of rest, postural, action, standing and walking tremors

### Chronic treatment {#Sec11}

Chronic dopaminergic treatments administration improved all the types of tremors in tDLB (Wilcoxon test, *Z* values range −2.9 and −4.2; *p* \< 0.005) and all but action tremor in tPD (Wilcoxon test, *Z* values range −2.9 and −6.4; *p* \< 0.005). The typical standing tremor observed in tDLB improved from a mean TRGRS score of 2.25 to a mean TRGRS score of 1.42 after chronic [l]{.smallcaps}-Dopa administration. Total disappearance of tremor was observed in 12 tDLB and 14 tPD patients.

Effect of chronic dopaminergic treatment on clustered TRGRS items is illustrated in Fig. [4](#Fig4){ref-type="fig"}b. Mixed tremor with overflow on a standing position disappeared in one PD and in 12 out of 15 DLB patients. In all DLB patients TRGRS scores for rest, postural or intentional tremor components during [l]{.smallcaps}-Dopa treatment were reduced by 1--2 points on the TRGRS. Comparison of scores prior to treatment and scores after six months of treatment demonstrated that there was a 1--2 point reduction in the TRGRS score, corresponding to reduction of 50--90 % for rest, 60--90 % for postural and 60 % for the intentional component. Head and chin tremor was reduced from a score of 2--3 to 1 point in 4 DLB and 1 PD patient, and was abolished (from score 2--0) in 1 DLB and two PD patients, while these tremors were not modified in three DLB and six PD patients.

During chronic [l]{.smallcaps}-Dopa treatment (mean daily dose 300 ± 45.5 mg), two patients (1 DLB, 1 PDD), whose mixed tremor had been suppressed, showed a residual small amplitude cortical mini-polymyoclonus in the fingers, evident in outstretched horizontal position of the arms, already described in association with Lewy body pathology \[[@CR3]\] which was undetectable before [l]{.smallcaps}-Dopa administration, due to superimposition of postural tremor components.

### Primidone {#Sec12}

The eight DLB patients who received primidone (125 b.i.d. in 6, 250 mg b.i.d. in two) prior to referral to our clinics presented with mixed tremors, including postural action tremor with TRGRS score from 2 to 4 and variable rest tremor (TRGRS score 1--3). Four of them presented with standing tremor (TRGRS score 2,3). Primidone withdrawal was not followed by tremor worsening (Wilcoxon test, *Z* = −1.13; *p* = 0.25) with no differences between tremor types. In the same patients chronic [l]{.smallcaps}-Dopa therapy significantly reduced tremor scores (mean Total TRGRS score difference = 14.1; Wilcoxon test, *Z* value = −2.52, *p* = 0.012). Online Resource 4 shows detailed results.

Discussion {#Sec13}
==========

Our cohort study showed that tremor occurred in 45 % of DLB patients compared to 59 % of PD patients; thus it confirmed that tremor is less frequent in DLB than PD but challenged the assumption that tremor is rare in DLB.

Thus, our findings suggest that DLB, indeed, consists of tremulous and non tremulous variants.

Furthermore our data shows that tremor in DLB patients is in high prevalence a bilateral mixed tremor (postural, action, standing with head tremor) and we demonstrated that it shows responsiveness to [l]{.smallcaps}-Dopa treatment, but do not respond to primidone or alcohol.

Strengths and limitations {#Sec14}
-------------------------

The comprehensive nature of our assessments, including the application of established diagnostic criteria \[[@CR1]\] and of SPECT and EEG assessments, of treatment protocols with [l]{.smallcaps}-Dopa and alcohol, and of a wide spectrum of neuropsychological test batteries and the two year follow-up ensured a high degree of diagnostic certainty, within the limit of clinical studies not supported by neuropathology \[[@CR3], [@CR15], [@CR29], [@CR30]\]. In addition we could exclude that G20195 mutations in the LRRK2 gene, which associate with tremors \[[@CR27]\], were present in our cohort population.

A definite limitation is that our findings could not be supported by neuropathological ascertainments, as no ascertainment exists for ET.

However, the majority of clinical studies, same as ours, could not benefit from the support of neuropathology, but yet were considered staminal studies \[[@CR3], [@CR14], [@CR18]\].

A second possible limitation is the ascertainment bias of patients referred to our centre, as we included all patients who were referred to both our movement disorders and memory clinics following procedures that underline our specific scientific interest \[[@CR29]--[@CR32]\]. However the prevalence of tremor in our cohort (45 %) was not different from prevalence rates found in earlier studies \[[@CR2], [@CR3]\] conducted in memory clinics.

Characterisation of tremulous DLB (tDLB) {#Sec15}
----------------------------------------

The tDLB patients had shorter disease duration and better MMSE and DRS2 scores than non-tremulous ones and this may be due to the fact that individuals with the obvious symptom of tremor are referred earlier in their disease course. The tDLB patients were also modestly older than the nontremulous ones. We believe, however, that older age does not indicate that senile tremor was overlapping to DLB features, as the phenomenology and opposite responses to [l]{.smallcaps}-Dopa and alcohol evidence that tremor in tDLB was characterized by specific patterns.

In detail beyond rest tremor, the different tremor patterns observed in tDLB were head and face \[[@CR7], [@CR8]\], postural and action, re-emergent \[[@CR9]\], walking and standing (also called pseudo orthostatic) \[[@CR5], [@CR11], [@CR12]\] tremors, which are reported to occur in PD less frequently than rest tremor. In addition, the standing/pseudo-orthostatic tremor \[[@CR5], [@CR11]--[@CR13]\] appeared to be particularly common in tDLB patients. The standing posture revealed one further feature of this mixed tremor: there was overflow from arms to other body districts in a few seconds which might be considered a particularly severe example of the specific re-emergent postural tremor described in PD \[[@CR8]\], which is different from postural tremor of ET, because in ET, posture elicits tremor immediately, while the re-emergent tremor appears with a delay when acquiring the posture (10 ± 4 in our cohort).

Due to the complex and variable expression of tremors in DLB the regression analysis was weak at identifying a single tremor type which was predictive of DLB although the presence of standing tremor correctly predicted (regression and ROC analysis) in about half of the tDLB patients, with the same tremor being absent in ET and very rare in PD.

Differential diagnosis was helped by identification of 4 tremor types: walking, re-emergent and standing tremor were observed only in tDLB and tPD patients while the voice tremor was only observed in ET patients.

Treatment of tremors in DLB {#Sec16}
---------------------------

The second relevant finding of our cohort study was that in DLB all types of tremors including head, mixed and standing tremor showed a significant response to acute [l]{.smallcaps}-Dopa challenge or chronic [l]{.smallcaps}-Dopa treatment and were not modified by alcohol administration according to standard tremor assessment protocols \[[@CR35], [@CR36]\], whereas ET was reduced by alcohol. This not only has implications for clinical practice but also for the aetiology of tremor in DLB as it suggests that tremor in DLB, when present, arises from dysfunction of the dopaminergic system and is a unitary disorder specific to this condition rather than a variant of ET or a senile tremor, or is due to concomitant occurrence of both ET and DLB.

Further support to this conclusion was obtained in the present study by the observation of the effect of primidone withdrawal in eight patients who had received primidone because of the initial diagnosis of ET but who presented with all core and supportive consensus elements of DLB. Primidone withdrawal had no effect on tremor in these patients, also alcohol administration had no effect, while their tremor was significantly reduced by [l]{.smallcaps}-Dopa (Online Resource 4).

This minor part of our study, restricted to a small number of patients, together with the other data, suggests a further clinically relevant conclusion: the mixed pattern of tremor (given the prominent action-postural components) in DLB could be the source of possible misdiagnosis.

Some DLB patients were inappropriately, yet temporarily, classified as having ET, but responses to treatment and results of the comprehensive DLB-consensus-based assessments, finally clarified the appropriate diagnosis (Fig. [1](#Fig1){ref-type="fig"}).

Our data thus would suggest that in some cases ET patients are actually misdiagnosed tDLB patients.

Albeit prudent considerations are needed, in the absence of neuropathology, this finding may provide additional clarity to the on-going debate \[[@CR38]\], opposing two factions, suggesting \[[@CR16]--[@CR21]\] or denying \[[@CR22]--[@CR24]\] the possibility that ET might evolve to PD or DLB, implicitly challenging the assumption that the three do represent distinct clinical entities rather than syndromes.

While recent studies \[[@CR39], [@CR40]\] might further help to clarify this controversy, by adding new concepts to the debate, our concluding remark would be focused to a simple take home message: the appropriate examination and investigation of patients with tremor should not be simply addressed to motor aspects but should also consider non-motor features and specifically the core and supportive features of DLB \[[@CR1]--[@CR3]\] i.e., cognitive, visuo-spatial and dysexecutive abnormalities, RBD, and EEG abnormalities, before reaching definite conclusions.
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